Cell-penetrating peptides

The process of introducing drugs into cells has always proved a major challenge for scientists.However, cell-permeable peptides (CPPs) have the ability to enter the plasma membrane of a cell independent of a membrane receptor. They are usually small peptides 10–30 residues in length with positively charged amino acid sequences. CPPs are capable of delivering biologically active cargo to the cell interior. The desired therapeutic cargo could be attached to a CPP and then delivered to an intracellular target, thereby overcoming the entry restrictions set by the plasma membrane. CPPs have gained a widespread popularity as very promising non-viral transmembrane delivery vectors. Although they have been used successfully for carrying different cargoes of varying size and nature (plasmid DNA, peptides, proteins, nanoparticles, and quantum dots, etc.), the most rapid progress has been made with the delivery of oligonucleotides (ONs). 


DGpeptides Co., Ltd.has succeeded in synthesizing large amount of cell-permeable peptides and here are part of them below:

Name Cell-penetrating peptides Name Cell-penetrating peptides
2 DSLKSYWYLQKFSWR (Kondo et al. 2012) MPG GALFLGFLGAAGSTMGA cysteamide (Morris et al. 1997)
18A DWLKAFYDKVAEKLKEAF (Datta et al. 2000) MPG GALFLGFLGAAGSTMGASQPKKKRKV cycteamide (Deshayes et al. 2005)
α1H KSKTEYYNAWAVWERNAP (Gomarasca et al. 2017) MPG-8 AFLGWLGAWGTMGWSPKKKRK (Crombez et al. 2009b)
α2H GNGEQREMAVSRLRDCLDRQA (Gomarasca et al. 2017) mRVG YTIWMPENPRPGTPCDIFTKSRGKRASNGGGRRRRRRRRR(Villa-Cedillo et al. 2017)
A22p HTPGNSNKWKHLQENKKGRPRR (Shin et al. 2014) MT23 LPKQKRRQRRRM (Zhou et al. 2017)
Ac-18A-NH2 DWLKAFYDKVAEKLKEAF) (Wimley and White 2000) mtCPP1 r-Dmt-OF (Cerrato et al. 2015)
aCPP Typical sequence R9GPLGLAGE8 (Li et al 2015) MTM AAVALLPAVLLALLAP (Fletcher et al. 2010)
AdVpVI(33-55) Ac-GAFSWGSLWSGIKNFGSTVKNYG (Murayama et al. 2016) MTD84 AVALVAVVAVA (Lim et al. 2014)
AIP6 RLRWR (Wang et al. 2011) MTP MLSLRQSIRFFK (Chuah et al. 2015a, b)
all-d DsC18 Glrkrlrkfrnkikek (Bergmann et al. 2017) MTS KGEGAAVLLPVLLAAPG (Zhao et al. 2001)
αgliadin(31-43) LGQQQPFPPQQPY (Paolella et al. 2018) MTS1 AAVLLPVLLAAP (Rojas et al. 1998)
Alyteserin-2a ILGKLLSTAAGLLSNL (Conlon et al. 2013) Mut3DPT-C9h VKKKKIKAEIKIYVETLDDIFEQWAHSEDL (de la Torre et al. 2017)
ANG TFFYGGSRGKRNNFKTEEY (Demeule et al. 2008) Myr-ApoE Myr-LRKLRKRLLR (Tajik-Ahmadabad et al. 2017)
ApoE(141–150) Ac-LRKLRKRLLRX-Bpg-G (Shabanpoor et al. 2017) New modalities Polycyclic, hairpin, stapled peptides for delivery (Valeur et al. 2017, Waldmann et al. 2017)
ApoE-derived Ac-LRKLRKRLLR (Tailhades et al. 2017) NF1 Stearyl-AGY(PO3)LLGKTNLKALAALAKKIL (Arukuusk et al. 2013)
Arf(1-22) MVRRFLVTLRIRRACGPPRVRV (Johansson et al. 2008) NF51 δ-(Stearyl-AGYLLG)OINLKALAALAKKIL (Arukuusk et al. 2013)
AT1002 FCIGRL (Gopalakrishnan et al. 2009) NF55 δ-(Stearyl-AGYLLG)OINLKALAALAKAIL (Freimann et al. 2016)
AT1AR(304-318) FLGKKFKKYFLQLLK (Östlund et al. 2005) NLS PKKKRKV (Yoneda et al. 1992).
Bac7 RRIRPRPPRLPRPRPRPLPFPRPGPRPIPRPL (Sadler et al. 2002) NLS-StAx-h stapled RRWPRXILDXHVRRVWR (Dietrich et al. 2017)
BGPC7-FHV RRRRNRTRRNRRRVR-RRFYGPV (Wongso et al. 2017) NoLS KKRTLRKNDRKKRC (Yao et al. 2015)
Bim EIWIAQELRRIGDEFNAYYARLLC (Kim et al. 2017) Novicidin KNLRRIIRKGIHIIKKYF (Milosavljevic et al. 2016)
BP16 KKLFKKILKKL (Soler et al. 2014) NPFSD VLTNENPFSDP (Gong et al. 2016)
BP100 KKLFKKILKYL (Eggenberger et al. 2009) NYAD-1 stapled ITFEDLLDYYGP (Zhang et al. 2008)
BPP13a GGWPRPGPEIPP (Sciani et al. 2017) Oct4-PTD DVVRVWFCNRRQKGKR (Adachi et al. 2017)
bPrPp(1-30) MVKSKIGSWILVLFVAMWSDVGLCKKRPKP (Magzoub et al. 2006) P007 Ac-(RAhxR)4-Ahx-βAla (Greer et al. 2014)
BR2 RAGLQFPVGRLLRRLLR (Lim et al. 2013) P1 LRRWSLG (Peng et al. 2017b)
Buforin II TRSSRAGLQFPVGRVIIRLLRK (Park et al.1998) P2 WKRTLRRL (Peng et al. 2017b)
Buforin IIb RAGLQFPVG[RLLR]3 (Lee et al. 2008) P3 YGRKKRRQR (Tan et al. 2006)
C6M1 RLWRLLWRLWRRLWRLLR (Jafari et al. 2014) P7 RRMKWKK (Watson et al. 2017)
C105Y CSIPPEVKFNKPFVYLI (Rhee and Davis 2006) P11 YGRKKRRQRRR (Zhao et al. 2011)
CADY GLWRALWRLLRSLWRLLWRA cycteamide (Crombez et al. 2009a) P11 HSDVHK (Bang et al. 2011)
CAR CARSKNKDC (Toba et al. 2014) P11LRR P11LRR (Li et al. 2010)
CA-Tat KWKLFKKYGRKKRRQRRR (Lv et al. 2017) P14LRR (PLPRPR)4 (Brezden et al. 2016)
CB5005 M KLKLALALALA (Zhang et al. 2016) p18 LSTAADMQGVVTDGMASG (Taylor et al. 2009)
CDB3 REDEDEIEW (Issaeva et al. 2003) P21 KRKKKGKGLGKKRDPCLRKYK (Dixon et al. 2016)
CendR RPARPAR (Hu et al. 2014) P28 LSTAADMQGVVTDGMASGLDKDYLKPDD, Leu50-Asp77 of azurin (Yamada et al. 2016)
cFΦR4 cyclic FΦRRRRQ (Qian et al. 2014) p28 FLHSGTAVTCTYPALTPQWEGSDCTHRL (Signorelli et al. 2017)
CGKRK CGKRK (Griffin et al. 2017) p53 peptide MO6 Stapled TSF*EYWYLL* (Chee et al. 2014)
CIGB-300 cyclic CWMSPRHLGTC-Tat (Perera et al. 2012) PAF26 Ac-rkkwfw (Lopez-Garcia et al. 2002)
CIGB-552 Ac-HARIKpTFRRlKWKYKGKFW (Fernandez Masso et al. 2013) PAS GKPILFF (Woldetsadik et al. 2017)
CLIP6 KVRVRVRVpPTRVRERVK (Soudah et al. 2017) pCLIP6 KVRVRVRVpP(pT)RVRERVK (Chen et al. 2017b)
CooP ACGLSGLGVA (Hyvonen et al. 2014) pD-SP5 riPRPSPKMGV(pS)VS (Chen et al. 2017b)
CpMTP ARLLWLLRGLTLGTAPRRA (Jain and Chugh 2016) PenetraMax KWFKIQMQIRRWKNKR, L- and D- (Khafagy el et al. 2015)
CPNT STSGTGKMTRAQRRAAARRNRA (Qi et al. 2011) Penetratin RQIKIWFQNRRMKWKK (Derossi et al. 1994)
CPP1 (KFF)3K (Patel et al. 2017) Pep-1 KETWWETWWTEWSQPKKKRKV cysteamide (Morris et al. 1997)
CPP33 RLWMRWYSPRTRAYG (Lin et al. 2018) pepM KLFMALVAFLRFLTIPPTAGILKRWGTI (Freire et al. 2014)
CPP-C PIEVCMYREP (Nakayama et al. 2011) pepR LKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRR (Freire et al. 2014)
CPPecp NYRWRCKNQN (Fu et al. 2017) Pept1 PLILLRLLRGQF (Marks et al. 2011)
C-peptide GPGLWERQAREHSERKKRRRESECKAA (Fan et al. 2016) Peptide 599 GLFEAIEGFIENGWEGMIDGWYGGGGRRRRRRRRRK(Alexander-Bryant et al. 2015)
CRGDK CRGDK (Zhao et al. 2018) Pep42 Cyclic CTVALPGGYVRVC (Kim et al. 2006)
Crotamine YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG(Rodrigues et al. 2012) PepNeg SGTQEEY (Neves-Coelho et al. 2017)
cSN50 AAVALLPAVLLALLAPVQRKRQKLMP (Torgerson et al. 1998) PepFect6 Stearyl-AGYLLGK(εTMQ)INLKALAALAKKIL, PF6 (El-Andaloussi et al. 2011)
65-2CTS CPYVNQRPQKARYRNG (Percipalle et al. 2003) PepFect14 Stearyl- AGYLLGKLLOOLAAAALOOLL (Ezzat et al. 2011)
CWR8K CWR8K (Sasaki et al. 2008) PG1 RGGRLCYCRRRFCVCVGR (Liu et al. 2013b)
CyLoP-1 CRWRWKCCKK (Ponnappan et al. 2017) pHLIP AEQNPIY-WARYADWLFTTPLLLLDLALLV-DADEGT (Andreev et al. 2010)
Cyt c(77–101) GTKMIFVGIKKKEERADLIKKA (Howl and Jones 2015) PHPs H6-H10 peptides (Kimura et al. 2017)
DAG cyclic CDAGRKQKC (Mann et al. 2017) PIP1 RXRRXRRXRIKILFQNRRMKWKK (Ivanova et al. 2008)
D-JNKI-1 RPKRPTTLNLFPQVPRSQDT (Bonny et al. 2001) Pip5e RXRRBRRXRILFQYRXRBRXRB (Betts et al. 2012)
DK17 DRQIKIWFQNRRMKWKK (Bera et al. 2016) Pip6a Ac-RXRRBRRXRYQFLIRXRBRXRB (Lehto et al. 2014)
DLP ACKTGSHNQCG (Kumar et al. 2015) POD CGGG(ARKKAAKA)4 (Dasari et al. 2017)
DMBT1-derived GRVEVLYRGSW and GRVRVLYRGSW (Tuttolomondo et al. 2017) PR9 FFLIPKG-R9 (Liu et al. 2013a)
dNP2 KIKKVKKKGRK-KIKKVKKKGRK (Lim et al. 2015) PTD YARVRRRGPRRR (Dong et al. 2016)
DPV3 RKKRRRESRKKRRRES (Tacken et al. 2008) PTD3 R9-ETWWETWWTEW (Kizaka-Kondoh et al. 2009)
DPV1047 CVKRGLKLRHVRPRVTRMDV (De Coupade et al. 2005) PTD4 YARAAARQARA (McCusker et al. 2007)
DRTTLTN DRTTLTN (Gennari et al. 2016) Poly-Arg Most popular R7 - R12 (Mitchell et al. 2000, Futaki, 2006)
DS4.3 RIMRILRILKLAR (Jeong et al. 2014) pVEC LLIILRRRIRKQAHAHSK (Elmquist et al. 2001)
Dynorphin A YGGFLRRIRPKLKWDNQ (Marinova et al. 2005) Pyrrhocoricin VDKGSYLPRPTPPRPIYNRN (Otvos et al. 2000)
EA GLKKLAELAHKLLKLGC (Yang et al. 2014) R4K1 Stapled Ac-RRRRKS*LHRS*LQDS (Speltz et al. 2018)
EB1 LIRLWSHLIHIWFQNRRLKWKKK (Lundberg et al. 2007) R6dGR R6dGR (Wang et al. 2017)
EF GLKKLAELFHKLLKLGC (Yang et al. 2014) R8 R8 (Wender et al. 2001)
EHB RCSHYTGIRCSHMAATTAGIYTGIRCQHVVL-C6H (Cao et al. 2018) R8-dGR R8dGR (Liu et al. 2016b)
EPRNEEK EPRNEEK (Orihuela et al. 2009) R9-H4A2 Ac-YR9-HAHAHH (Okitsu et al. 2017)
F3** diphosphorylated dipeptide (Miao et al. 2016) R6W3 R6W3 (Bechara et al. 2013)
G4R9L4 G4R9L4 (Ramakrishna et al. 2014) R10W6 R10W6 (Bechara et al. 2013)
GALA WEAALAEALAEALAEHLAEALAEALEALAA (Li et al. 2004) RA9 RRAARRARR (Alhakamy et al. 2013)
GeT KIAKLKAKIQKLKQKIAKLK (Rakowska et al. 2014) RALA WEARLARALARALARHLARALARALRACEA (McCarthy et al. 2014)
gH625 HGLASTLTRWAHYNALIRAF (Galdiero et al. 2015) RDP CKSVRTWNEI IPSKGCLRVG GRCHPHVNGG GRRRRRRRRC(Xiao et al. 2017)
Gi3α(346-355) KNNLKECGLY (Jones et al. 2005) REDV REDV (Yang et al. 2016)
Glu-Lys EEEAAKKK (Lewis et al. 2010) RF GLKKLARLFHKLLKLGC (Yang et al. 2014)
GV1001 EARPALLTSRLRFIPK (Kim et al. 2016a) cRGDfC Cyclic RGDfC (Wada et al. 2017)
GWH1 GYNYAKKLANLAKKFANALW (Serna et al. 2017) iRGD Cyclic CRGDKGPDC (Peng and Kopecek, 2015)
H2A derived SGRGKQGGKARAKAKTRSSRAGLQFPVGRVHRLLRKG(Rosenbluh et al. 2004) RGE RGERPPR (Yu et al. 2017)
H6R6 H6R6 (Sun et al. 2017) RH9 RRHHRRHRR (Alhakamy et al. 2013)
H16 H16 (Iwasaki et al. 2015) RL9 RRLLRRLRR (Alhakamy et al. 2013)
HA2(1-23) GLFGAIAGFIENGWEGMIDGWYG (Esbjörner et al. 2007) RL16 RRLRRLLRRLLRRLRR (Joanne et al. 2009)
HAIYPRH HAIYPRH (Shteinfer-Kuzmine et al. 2017) RT53 RQIKIWFQNRRMKWKKAKLNAEKLKDFKIRLQYFARGLQVYIRQLRLALQGKT (Jagot-Lacoussiere et al. 2016)
hBD3-3 GKCSTRGRKCCRRKK (Lee et al. 2015b) RTP004 RKKRRQRRRG-K15-GRKKRRQRRR) (Lee et al. 2015a)
HBP GKRKKKGKGLGKKRDPCLRKYK (Luo et al. 2016) RV24 RRRRRRRRRGPGVTWTPQAWFQWV (Lo and Wang, 2012)
hLF KCFQWQRNMRKVRGPPVSCIKR (Duchardt et al. 2009) RVG YTIWMPENPRPGTPCDIFTNSRGKRASNG (Kumar et al. 2007)
Hph-1 YARVRRRGPRR (Jung et al. 2011) RVG-9R YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRR(Rassu et al. 2017)
HR9 CH5-R9-H5C (Liu et al. 2013a) RVG29 YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRR(Villa-Cedillo et al. 2017)
Hst5 DSHAKRHHGYKRKFHEKHHSHRGY (Luque-Ortega et al. 2008) RW9 RRWWRRWRR (Alhakamy et al. 2013)
I1WL5W WKKIWSKIKKLLK (Bi et al. 2014) RW16 RRWRRWWRRWWRRWRR (Jobin et al. 2013)
I4WL5W IKKWWSKIKKLLK (Bi et al. 2014) (RXR)4 (R-Ahx-R)4 (Saleh et al. 2010)
ID No.2 MAAWMRSLFSPLKKLWIRMH (Eudes and Macmillan 2014) (rXr)4 (r-Ahx-r)4 (Vij et al. 2016b)
IMT-P8 RRWRRWNRFNRRRCR (Gautam et al. 2016) S155 VKKKKIKREI-KIAAQRYGRELRRMADEFHV (Haidar et al. 2017)
INF GLFEAIEGFIENGWEGMIDGWYGC (Pichon et al. 1997) S4(13)-PV ALWKTLLKKVLKAPKKKRKV (Mano et al. 2007)
iNGR CRNGRGPDC (Alberici et al. 2013) SAP VRLPPPVRLPPPVRLPPP (Pujals et al. 2006)
isl-1 RVIRVWFQNKRCKDKK (Kilk et al. 2001) SAP(E) VELPPPVELPPPVELPPP (Martin et al. 2011)
JB9 cskc (Basu and Wickstrom, 1997) all-D-SAP (vrlppp)3 (Pujals et al. 2007)
JB434 R9GGLAA-Aib-SGWKH6 (Sangtani et al. 2018) SAPSp-lipo stearyl-GGGGHGAHEHAGHEHAAGEHHAHE (Suzuki et al. 2017)
KAFAK KAFAKLAARLYRKALARQLGVAA (Bartlett et al. 2013) SAR6EW SAR6EW (Im et al. 2017)
KALA WEAKLAKALAKALAKHLAKALAKALKACEA (Wyman et al. 1997) sC18 GLRKRLRKFRNKIKEK (Oren et al. 1999)
Kalata B1 polycyclic CGETCVGGTCNTPGCTCSWPVCTRNGLPV (Daly et al. 1999) (sC18)2 (GLRKRLRKFRNKIKEK)2 (Gronewold et al. 2017)
(KFF)3K (KFF)3K (Rownicki et al. 2017) SMTP motif, LRLLR (Fuselier and Wimley, 2017)
K-FGF AAVLLPVLLAAP (Lin et al. 1995) SPACE Cyclic ACTGSTQHQCG (Hsu and Mitragotri, 2011)
KH (KH)9 (Chuah et al. 2016) SRCRP2-11 GRVEVLYRGSW (Tuttolomondo et al. 2017)
KLA KLAKLAKKLAKLAK (Huang et al. 2017) STR-KV H3K3V6 (Pan et al. 2016)
KLAK KLALKLALKALKAALKLA (Oehlke et al. 1998) SS-02 Dmt-r-FK (Alta et al. 2017)
KLA-R7 KLAKLAKKLAKLAKGGRRRRRRR (Lemeshko, 2013) SS-20 F-r-FK (Alta et al. 2017)
KP MAPTKRKGSCPGAAPNKKP (Villa-Cedillo et al. 2017) SS-31 r-Dmt-KF (Zhao et al. 2005)
KST peptide STGKANKITITNDKGRLSK (Adachi et al. 2017) SynB1 RGGRLSYSRRRFSTSTGR (Rousselle et al. 2000)
L1−6 PLILLRLLR (Schmidt et al. 2017) T2 LVGVFH (Kumar et al. 2012)
L5a RRWQW (Liu et al. 2016a) Tat(49-57) RKKRRQRRR (Vives et al. 1997a)
L17E IWLTALKFLGKHAAKHEAKQQLSKL (Akishiba et al. 2017) Tat(48-60) GRKKRRQRRRPPQ (Vives et al. 1997b)
lactoferrampin(265- 284) DLIWKLLSKAQEKFGKNKSR (Reyes-Cortes et al. 2017) Tat(44-57) CGISYGRKKRRQRRR (Niesner et al. 2002)
lactoferricin(17-30) FKCRRWQWRMKKLG (Reyes-Cortes et al. 2017) Tat(37-72) CFITKALGISYGRKKRRQRRRPPQGSQT-HQVSLSKQ (Fawell et al. 1994)
lactoferrin(19-40) KCFMWQEMLNKAGVPKLRCARK (Duchardt et al. 2009) Tat analog GRKKRRQR (Nguyen et al. 2008)
LAH1 KKLALALALALHALALALALKKA (Moulay et al. 2017) Tat-LK15 Tat-KLLKLLLKLLLKLLK (Peng et al. 2017a)
LALF(31-52) HYRIKPTFRRLKWKYKGKFW (Yanez et al. 2017) TCTP MIIFRALISHKK (Bae et al. 2016)
LB FKCRRWQWRMKKLGAPSITCVRRAF) (Liu et al. 2013b) TD-1 ACSSSPSKHCG (Chen et al. 2006)
L-CPP LAGRRRRRRRRRK (Liu et al. 2006) TD2.2 SYWYRIVLSRTGRNGRLRVGRERPVLGESP (Heffernan et al. 2012)
LDP-NLS KWRRKLKKLRPKKKRKV (Ponnappan and Chugh, 2017) TH peptide GYLLGHINLHHLAHL-Aib-HHIL (Chen et al. 2017a)
LE10 LELELELELELELELELELE (Antunes et al. 2013) TM2 PKKGSKKAVTKAQKKDGA (Kochurani et al. 2015)
LF chimera FKCRRWQWRMKKLG-K-RSKNKGFKEQAKSLLKWILD(Reyes-Cortes et al. 2017) Transportan GWTLNSAGYLLGKINLKALAALAKKIL, TP (Pooga et al. 1998)
linTT1 AKRGARSTA (Hunt et al. 2017) TP10 AGYLLGKINLKALAALAKKIL (Soomets et al. 2000)
LK LKKLLKLLKKLLKLAG (Kim et al. 2016b) TPk VRRFkWWWkFLRR (Bahnsen et al. 2015)
LL37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (Kim et al. 2016b) Tpl KWCFRVCYRGICYRRCRGK (Jain et al. 2015)
LLIIL LLIIL (Alaybeyoglu et al. 2017) TPP TKDNNLLGRFELSG (Gehrmann et al. 2014)
LMWP VSRRRRRRGGRRRR (Chen et al. 2017d) TT1 CKRGARSTA (Paasonen et al. 2016)
LP-12 HIITDPNMAEYL (Kumar et al. 2015) vAMP 059 INWKKWWQVFYTVV (Dias et al. 2017)
LPAs RCnRCnK (Gupta et al. 2011) vCPP 0769 RRLTLRQLLGLGSRRRRRSR (Dias et al. 2017)
LTV LTVSPWY (Chopra 2012) vCPP 2319 WRRRYRRWRRRRRWRRRPRR (Dias et al. 2017)
lycosin-I RKGWFKAMKSIAKFIAKEKLKEHL (Tan et al. 2017) VDAC(1-26) MAVPPTYADLGKSARDVFTKGYGFGL (Smilansky et al. 2015)
Lyp1 CGNKRTRGC (Fogal et al. 2008) VP22 NAATATRGRSAASRPTQRPRAPARSASRPRRPVQ (Elliott and O'Hare, 1997)
M918 MVTVLFRRLRIRRACGPPRVRV (El-Andaloussi et al. 2007) V peptide TVDNPASTTNKDKLFAVRK (Manosroi et al. 2014)
Maurocalcine GDCLPHLKLCKENKGCCSKKCKRRGTNIEKRCR (Poillot et al. 2010) VT5 DPKGDPKGVTVTVTVTVTGKGDPKPD (Oehlke et al. 1997)
MAP KLALKLALKALKAALKLA (Oehlke et al. 1998) W(RW)4 W(RW)4 (Nasrolahi Shirazi et al. 2013)
MAP12 LKTLTETLKELTKTLTEL (Oehlke et al. 2002) Xentry LCLR (Montrose et al. 2014)
MCoTI-I polycyclic SGSDGGVCPKILQRCRRDSDCPGACICRGNGYCG(Camarero, 2017) X-pep MAARLC (Adachi et al. 2017)
MCoTI-II polycyclic CPKILKKCRRDSDCPGACICRGNGYCGSGSDGGV(Huang et al. 2015) YKA YKALRISRKLAK (Desai et al. 2014)
MFK MFKLRAKIKVRLRAKIKL (Samuels et al. 2017) YTA2 YTAIAWVKAFIRKLRK (Lindgren et al. 2006)
Mgpe9 CRRLRHLRHHYRRRWHRFRC (Vij et al. 2016a) YTA4 IAWVKAFIRKLRKGPLG (Lindgren et al. 2006)
MitP INLKKLAKL(Aib)KKIL (Howl et al. 2018) Z2 FWIGGFIKKLKRSKLA (Chen et al. 2017c)
m(KLA)-iRGD klaklakklakla-K-GG-iRGD (Qifan et al. 2016) Z3 FKIKKFIGGLWRSKLA (Chen et al. 2017c)
MMGP1 MLWSASMRIFASAFSTRGLGTRMLMYCSLPSRCWRK(Pushpanathan et al. 2013) Z12 KRYKNRVASRKCRAKFKQLLQHYREVAAAKSSENDRLRLLLK(Derouazi et al. 2015)
MPER fragment ELDKWASLWNWFDITNWLWYIK (Song et al. 2009) ZXR-1 FKIGGFIKKLWRSKLA (Chen et al. 2017c)


Note:

Ac=acetyl; 

Ahx or X=aminohexanoic acid; 

Aib=aminoisobutyric acid; 

B=β-alanine; 

Bpg=bishomopropargylglycine; 

Dmt=dimethyltyrosine; 

O=ornithine; pT=phosphoryl-Thr; 

pS=phosphoryl-Ser; 

Φ=l-2-naphthylalanine; 

ri=retro-inverso; 

*=staple tethering site